ArticleDiscover oncology2026
A seven-gene diagnostic and prognostic signature for papillary thyroid carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer; however, indeterminate cytology in fine-needle aspiration biopsy (FNAB) and the limited sensitivity of single-mutation-based biomarkers remain important clinical challenges. This study aimed to identify a robust multi-gene expression signature for diagnostic evaluation and exploratory prognostic assessment of PTC. An integrative bioinformatics framework was applied to TCGA-THCA RNA-sequencing data (505 tumors and 59 normal samples). Differentially expressed genes were subjected to LASSO regression to construct a diagnostic model, which was externally validated in two independent GEO cohorts (GSE33630 and GSE60542). A seven-gene signature consisting of four upregulated genes (GABRB2, SERINC2, PTCHD4, HAPLN1) and three downregulated genes (SLC6A15, UGT2B11, GRIA1) demonstrated excellent diagnostic performance in the discovery cohort (AUC = 0.995) and remained highly accurate in external validation datasets (AUC = 0.940 and 0.938). Kaplan-Meier analysis showed significant stratification for disease-free interval (p = 0.034), although this association did not remain independent in multivariable analysis. Exploratory analyses suggested potential epigenetic regulation of several genes and distinct patterns in immune microenvironments between risk groups. Overall, these findings reveal a robust seven-gene expression signature with strong diagnostic capacity and potential prognostic relevance in PTC, highlighting its value for molecular characterization. However, further biological validation and prospective evaluation in clinically relevant cohorts are required before translational applicability can be established.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.